Monkeypox <br />Vaccine Maker , Expresses Concern , Over Dose-Splitting Plan.<br />Bavarian Nordic makes the only monkeypox vaccine currently authorized by the Food and Drug Administration (FDA).<br />The CEO of the company recently expressed concern about the Biden administration's plans to mitigate a vaccine shortage by splitting doses.<br />CEO Paul Chaplin expressed his concerns in a letter recently sent to Health and Human Services Secretary (HHS) Xavier Becerra.<br />We do have some reservations … due to the very limited safety data available, Paul Chaplin, Bavarian Nordic CEO, <br />via 'The Washington Post'.<br />According to Chaplin's letter, more studies to determine the efficacy of a split vaccine "would have been prudent.".<br />His letter also states that the company has received numerous "calls from U.S. state government officials <br />with questions and concerns.”.<br />Responding to news of the vaccine maker's concerns, HHS Secretary Xavier Becerra expressed confidence with the Biden administration's plan.<br />We’ve had conversations with them about this, and so has FDA, Xavier Becerra, HHS Secretary, via 'The Washington Post'.<br />We wouldn’t have moved forward unless we thought it was safe and effective, and if FDA hadn’t dotted its I’s and crossed its T’s, Xavier Becerra, HHS Secretary, via 'The Washington Post'.<br />Biden administration officials have speculated that Bavarian Nordic could be primarily concerned with a loss of profit.<br />... though Bavarian Nordic officials are adamant that the concerns of the company are safety focused.<br />Officials connected to the U.S. monkeypox vaccine plan call it a "game changer.".<br />It’s safe, it’s effective, and it will significantly scale the volume of vaccine doses available, Robert J. Fenton Jr., U.S. Monkeypox Response Co-Ordinator, via 'The Washington Post'
